Xoma Corporation is a biotechnology company focused on the acquisition and monetization of pharmaceutical royalty streams. Rather than developing its own drugs, Xoma strategically partners with and invests in a portfolio of clinical and commercial stage therapies, earning income through royalty payments on existing and future product sales. This model provides the company with diversified exposure to innovation across the biopharmaceutical sector while minimizing the inherent risks and costs of drug discovery and development. Xoma’s portfolio includes royalties associated with therapies in various therapeutic areas, making it a key player in the financial ecosystem that supports pharmaceutical innovation. By purchasing royalty interests, Xoma Corporation enables its partners to unlock capital from their assets, supporting further research and business growth within the biotechnology and pharmaceutical industries.